Table 2.

Prognostic significance of patient characteristics at study entry determined by univariate survival analysis

CharacteristicsNo. of PatientsProbability of Remission at 1 yr (%)aPb
Age (yr)
    <4021520.830
    ≥402157
Duration of LMNc (mo)
    ≤618610.500
    >62352
Race/ethnicity
    non-Hispanic white12750.030
    black and Hispanic3047
Proteinuria (g/d)
    ≤519740.003
    >52339
GFR (ml/min per 1.73 m2)
    <7010400.410
    ≥703259
Hematocrit
    <3410500.550
    ≥343256
Anti dsDNA antibodies
    present9440.180
    absent3057
Treatmentd
    prednisone alone15270.007
    adjunctive IVCY or CSA2770
Angiotensin antagoniste
    yes16500.850
    no2658
  • a Remission is defined as complete or partial remission of proteinuria (see the Concise Methods section).

  • b Significance level for the Gehan test that evaluates the equality of the survival curves that were obtained for subgroups of patients identified according to the level of the prognostic variable.

  • c Information regarding the duration of clinically suspected LMN before study entry was available for 41 of 42 patients.

  • d Shows the probability of remission for all patients who were randomly assigned to either prednisone alone or one of the adjunctive immunosuppressive regimens of IVCY or CSA. Details of the analyses of therapeutic outcomes are shown in Figure 1.

  • e Shows the probability of remission for 16 patients who were on stable dosages of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker that began at least 1 mo before baseline testing and continued during the 12-mo protocol treatment period compared with 26 patients who were not on concurrent angiotensin antagonist therapy.